PROM1 and glioblastoma: For instance, Kim et al. developed a dual-targeting immunoliposome encapsulating TMZ by using angiopep-2 (for targeting the BBB) and anti-CD133 monoclonal antibody (for targeting the GBM stem cells) [80].